Avid Bioservices, Inc. CDMO
We take great care to ensure that the data presented and summarized in this overview for Avid Bioservices, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDMO
View all-
Black Rock Inc. New York, NY5.11MShares$62.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.19MShares$51.5 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.85MShares$47.3 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.82MShares$46.9 Million0.12% of portfolio
-
Altra Vue Capital, LLC Bellevue, WA3.8MShares$46.7 Million4.48% of portfolio
-
State Street Corp Boston, MA3MShares$36.9 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN2.93MShares$36.1 Million1.99% of portfolio
-
Royal Bank Of Canada Toronto, A62.83MShares$34.8 Million0.01% of portfolio
-
First Light Asset Management, LLC Edina, MN2.77MShares$34.1 Million2.75% of portfolio
-
Portolan Capital Management, LLC Boston, MA2.09MShares$25.8 Million1.9% of portfolio
Latest Institutional Activity in CDMO
Top Purchases
Top Sells
About CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Insider Transactions at CDMO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 14
2024
|
Jeanne Thoma Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,756
+36.97%
|
-
|
|
Dec 14
2024
|
Esther M. Alegria Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,756
+41.48%
|
-
|
|
Dec 14
2024
|
Joseph Carleone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,756
+17.03%
|
-
|
|
Dec 14
2024
|
Richard B Hancock Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,756
+15.64%
|
-
|
|
Dec 14
2024
|
Catherine J Mackey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,756
+38.15%
|
-
|
|
Dec 14
2024
|
Gregory Sargen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,756
+42.39%
|
-
|
|
Oct 14
2024
|
Matthew R. Kwietniak Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
119
-0.47%
|
$1,190
$10.15 P/Share
|
|
Oct 11
2024
|
Matthew R. Kwietniak Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
335
+1.3%
|
-
|
|
Oct 10
2024
|
Nicholas Stewart Green President & CEO |
SELL
Open market or private sale
|
Direct |
17,173
-7.04%
|
$171,730
$10.05 P/Share
|
|
Oct 10
2024
|
Matthew R. Kwietniak Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
982
-3.75%
|
$9,820
$10.05 P/Share
|
|
Oct 10
2024
|
Richard A. Richieri Chief Operations Officer |
SELL
Open market or private sale
|
Indirect |
201
-2.71%
|
$2,010
$10.05 P/Share
|
|
Oct 10
2024
|
Richard A. Richieri Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
2,031
-5.11%
|
$20,310
$10.05 P/Share
|
|
Oct 09
2024
|
Nicholas Stewart Green President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,512
+11.44%
|
-
|
|
Oct 09
2024
|
Matthew R. Kwietniak Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,763
+9.55%
|
-
|
|
Oct 09
2024
|
Richard A. Richieri Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
462
+5.86%
|
-
|
|
Oct 09
2024
|
Richard A. Richieri Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,506
+12.17%
|
-
|
|
Jul 15
2024
|
Richard A. Richieri Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
530
-1.52%
|
$4,240
$8.36 P/Share
|
|
Jul 15
2024
|
Matthew R. Kwietniak Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
307
-1.29%
|
$2,456
$8.36 P/Share
|
|
Jul 12
2024
|
Richard A. Richieri Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,469
+4.05%
|
-
|
|
Jul 12
2024
|
Matthew R. Kwietniak Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
881
+3.58%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 303K shares |
|---|---|
| Other acquisition or disposition | 13.7K shares |
| Open market or private sale | 56.9K shares |
|---|